NCT03979989View on ClinicalTrials.gov

Drug-drug Interaction Study to Evaluate the Effect of Omeprazole on CG5503 (Tapentadol)

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

September 28, 2005

Primary Completion Date

November 16, 2005

Study Completion Date

November 16, 2005

Conditions

Pharmacokinetic

Interventions

DRUG

Tapentadol IR capsule

Tapentadol IR capsule containing 93 mg tapentadol hydrochloride.

DRUG

Omeprazole capsule

Omeprazole capsule containing 40 mg omeprazole.

Trial Locations (1)

2170

J&JPRD Clinical Pharmacology Unit, Merksem

Sponsors

Lead Sponsor

Grünenthal GmbH

All Listed Sponsors

collaborator

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

lead

Grünenthal GmbH

INDUSTRY